drugset / Trial / NCT00886067

Positron Emission Tomography (PET) Study

NCT00886067

Phase 1 Completed 11 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.

Timeline

Start
2009-04
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1446 Small molecule Oral

Indications

No indication recorded.